YiSheng BioPharma
ROOM 309,Building10,NO.9 Tianfu Street,Biological
Daxing District
Beijing
102600
China
Tel: 8610-61253655
Fax: 8610-61253655
Website: http://www.yishengbio.com/
17 articles about YiSheng BioPharma
-
Yisheng Biopharma and Tavotek Biotherapeutics Announce Strategic Research Alliance for Development of YS-ON-001/002 and Tavo-301/303 Combination Therapy for Cancer Treatment
1/6/2020
Yisheng Biopharma Co., Ltd. and Tavotek Biotherapeutics announced that the companies have entered into a strategic research alliance and collaborate in the development involving their lead assets in oncology.
-
Yisheng Biopharma Receives GMP Certification from China NMPA for Production of Lyophilized Rabies Vaccine for Preventive Use
7/22/2019
The newly constructed state-of-art production facility is operated by the Liaoning Yisheng Biopharma subsidiary.
-
Yisheng Biopharma Receives IND Clearance from China NMPA to Initiate Clinical Trial of YS-ON-001 in the Treatment of Advanced Solid Tumors
6/27/2019
Yisheng Biopharma Co., Ltd. announced that it has received Investigational New Drug clearance from the National Medical Products Administration of China to initiate a clinical trial of YS-ON-001, a first-in-class immuno-oncology product for the treatment of advanced solid tumors.
-
Yisheng Biopharma Announces Clearance from China FDA to Proceed with PIKA Rabies Vaccine Clinical Study
10/8/2018
The PIKA rabies vaccine has the potential to become a "best-in-class" rabies vaccine.
-
Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia
7/19/2018
YiSheng BioPharma Co., Ltd. ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, today announced the grand opening of Anderson Biotech Company Limited and Royal OncoCare Hospitality as two wholly owned subsidiaries of Yisheng Biopharma in Cambodia. The two divisions represent the first expansion of Yisheng Biopharma business and product sales operations into an ASEAN member country.
-
Beijing-based Yisheng Biopharma Co. is celebrating this morning after its lead immunology treatment snagged a second Orphan Drug Designation from the U.S. Food and Drug Administration.
-
The US FDA Granted Orphan Drug Designation to Yisheng Biopharma's Biological Product for Pancreatic Cancer Treatment
2/26/2018
Yisheng BioPharma Co., Ltd. ("Yisheng Biopharma"), a biopharmaceutical company focusing on research, development, manufacturing, sales and marketing of immunological biologics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for its lead immuno-oncology candidate, YS-ON-001, for the treatment of pancreatic cancer.
-
YiSheng BioPharma Announces New Breakthrough Results On YS-ON-001 In Multiple Solid Tumor Experiments
8/30/2017
-
YiSheng BioPharma Starts China Phase I Trial Of Immuno-Oncology Candidate
5/4/2017
-
YiSheng BioPharma Starts Enrollment In Phase I Immuno-Oncology Clinical Trial Of YS-ON-001 In Patients With Advanced Solid Tumors
5/1/2017
-
US FDA Grants Orphan Drug Designation To YiSheng BioPharma's PIKA Rabies Vaccine
1/4/2017
-
YiSheng BioPharma Announces Completion Of Phase I Clinical Study Of A Novel Hepatitis B Vaccine With PIKA Adjuvant
11/21/2016
-
YiSheng BioPharma To Collaborate With The Scripps Research Institute On AIDS Vaccine
11/8/2016
-
YiSheng BioPharma Announces Research Collaboration With The Scripps Research Institute In Developing New AIDS Vaccine
11/7/2016
-
The US FDA Granted Orphan Drug Designation To YiSheng BioPharma's Biological Product For Hepatocellular Carcinoma
10/24/2016
-
YiSheng BioPharma Reports Early Success For Its Adjuvant In Ebola Vaccine
7/18/2016
-
YiSheng BioPharma And The United States Army Medical Research Institute Of Infectious Diseases Announce Positive Animal Results Of Vaccine Against Ebola Virus
7/14/2016